Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 1.Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

EP: 2.Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER

EP: 3.Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC

EP: 4.Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials

EP: 5.Exciting Data and Trials in Progress from ASCO 2024

EP: 6.Ongoing RCC Clinical Trials that may Impact Practice

EP: 7.Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes

EP: 8.Dr Voss Application of Updated KEYNOTE-564 Data

Now Viewing

EP: 9.Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition

EP: 10.World Health Organization (WHO) Classification Updates for Papillary RCC

EP: 11.Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC

EP: 12.The Role of Chemotherapy in nccRCC Treatment

EP: 13.Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape

EP: 14.Final Thoughts/Looking Forward

1. Please briefly mention the recent retrospective findings with cabo post-len + pembro – (Haro-Silerio, et al. ASCO GU 2024. Abstract 433) = How do you approach treatment post-IO?
2. Please highlight recent data from the LITESPARK-011 trial(NCT04586231) evaluating belzutifan + lenvatinib vs cabozantinib in advanced RCC after anti-PD-L1 therapy (Motzer, et al. Future Med, 2023

a. Please also briefly mention the significance of recent data from the phase 3 LITESPARK-005 trial (NCT04195750) assessing belzutifan versus everolimus in previously treated advanced RCC patients

i. Safety and Efficacy – (Albiges, et al. ESMO 2023. Abstract LBA88

ii. Patient reported outcomes – (Powles, et al. ASCO GU 2024. Abstract 361)

b.How does belzutifan fit into your treatment paradigm?